Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SIMCERE PHARMA's ENZESHU and ENDOSTAR Included in China's NRDL
Recommend 3 Positive 3 Negative 3 |
||||
|
||||
|
SIMCERE PHARMA (02096.HK) announced that on December 7, 2025, ENZESHU (Suvemcitug for injection) has been officially included in the "Drugs Catalogue for the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2025)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, and will take effect from January 1, 2026. In addition, ENDOSTAR (Recombinant Human Endostatin for Injection) has also successfully completed the renewal under the National Reimbursement Drug List (NRDL). AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
